Vivo Bio Tech
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
Vivo Bio Tech said 6,27,409 of the 25 lakh convertible equity warrants allotted to Dwight Technologies Private Limited on February 24, 2025 had expired on August 24 after not being exercised within their 18-month tenure. Issued at ₹45 each on a preferential basis, the warrants represented potential subscription proceeds of about ₹2.82 crore.
Powered by Tijori
Vivo Bio Tech said 6,27,409 of the 25 lakh convertible equity warrants allotted to Dwight Technologies Private Limited on February 24, 2025 had expired on August 24 after not being exercised within their 18-month tenure. Issued at ₹45 each on a preferential basis, the warrants represented potential subscription proceeds of about ₹2.82 crore.
Powered by Tijori
P.K.L. Solution Private Limited, part of Vivo Bio Tech's promoter group, sold 6,00,000 equity shares in an off-market transaction on August 21, 2026. The sale represented 2.70% of the company's voting capital and 2.05% on a diluted basis, leaving the seller with no shares.
Powered by Tijori
P.K.L. Solution Private Limited, part of Vivo Bio Tech's promoter group, sold 6,00,000 equity shares in an off-market transaction on August 21, 2026. The sale represented 2.70% of the company's voting capital and 2.05% on a diluted basis, leaving the seller with no shares.
Powered by Tijori
Vivo Bio Tech said 8.1 lakh of 12 lakh convertible equity warrants issued to promoters at ₹45 each had expired on August 21, 2026, after they were not exercised within their 18-month tenure. The expired warrants were held by Kompella Lopa Mudra and Kompella Modini and represented potential subscription proceeds of ₹3.645 crore.
Powered by Tijori
Vivo Bio Tech said 8.1 lakh of 12 lakh convertible equity warrants issued to promoters at ₹45 each had expired on August 21, 2026, after they were not exercised within their 18-month tenure. The expired warrants were held by Kompella Lopa Mudra and Kompella Modini and represented potential subscription proceeds of ₹3.645 crore.
Powered by Tijori
Shri Shri Resorts Private Ltd, a promoter group entity of Vivo Bio Tech, sold 10,00,000 equity shares on June 8, cutting its stake in the contract research organization to 0.30% from 4.81%. The transaction, executed on the open market of the BSE, reduced the entity's holding to just 67,000 shares. Vivo Bio Tech has a market capitalization of about ₹54 crore and had earlier announced plans to amalgamate Shri Shri Resorts, a development first disclosed in late May.
Powered by Tijori
Shri Shri Resorts Private Ltd, a promoter group entity of Vivo Bio Tech, sold 10,00,000 equity shares on June 8, cutting its stake in the contract research organization to 0.30% from 4.81%. The transaction, executed on the open market of the BSE, reduced the entity's holding to just 67,000 shares. Vivo Bio Tech has a market capitalization of about ₹54 crore and had earlier announced plans to amalgamate Shri Shri Resorts, a development first disclosed in late May.
Powered by Tijori
** Shares of Vivo Bio Tech VIVO.BO rise 11.8% to 41.66 rupees
** Drug development and discovery services provider secures pre-clinical testing contract worth 107.5 mln rupees ($1.2 mln) for a novel molecule
** Contract includes toxicity studies across multiple endpoints, assessing genetic safety, environmental risk assessment, and analytical services
** Trading vols at 213,150 shares so far, over 4x the 30-day average
** Stock up ~12% YTD
($1 = 87.0800 Indian rupees)
(Reporting by Vijay Malkar)
(([email protected];))
** Shares of Vivo Bio Tech VIVO.BO rise 11.8% to 41.66 rupees
** Drug development and discovery services provider secures pre-clinical testing contract worth 107.5 mln rupees ($1.2 mln) for a novel molecule
** Contract includes toxicity studies across multiple endpoints, assessing genetic safety, environmental risk assessment, and analytical services
** Trading vols at 213,150 shares so far, over 4x the 30-day average
** Stock up ~12% YTD
($1 = 87.0800 Indian rupees)
(Reporting by Vijay Malkar)
(([email protected];))
Jan 13 (Reuters) - Vivo Bio Tech Ltd VIVO.BO:
LAUNCHES LARGE ANIMAL FACILITY, OPERATIONS ALREADY COMMENCED
Source text: ID:nBSE21BrNV
Further company coverage: VIVO.BO
(([email protected];;))
Jan 13 (Reuters) - Vivo Bio Tech Ltd VIVO.BO:
LAUNCHES LARGE ANIMAL FACILITY, OPERATIONS ALREADY COMMENCED
Source text: ID:nBSE21BrNV
Further company coverage: VIVO.BO
(([email protected];;))
Jan 9 (Reuters) - Vivo Bio Tech Ltd VIVO.BO:
VIVO BIO TECH - APPROVED PREFERENTIAL ISSUE OF WARRANTS UPTO 450 MILLION RUPEES
Source text: ID:nBSE87ccwJ
Further company coverage: VIVO.BO
(([email protected];))
Jan 9 (Reuters) - Vivo Bio Tech Ltd VIVO.BO:
VIVO BIO TECH - APPROVED PREFERENTIAL ISSUE OF WARRANTS UPTO 450 MILLION RUPEES
Source text: ID:nBSE87ccwJ
Further company coverage: VIVO.BO
(([email protected];))
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Vivo Bio Tech do?
Vivo Bio Tech Ltd is a contract research company specializing in biotechnology and pharmaceutical drug discovery services. They offer a comprehensive range of services including insilico design, wet lab research, preclinical studies, and clinical trials.
Who are the competitors of Vivo Bio Tech?
Vivo Bio Tech major competitors are Jeevan Scientific, Zenotech Labs., Dishman Carbogen Amc, Sun Pharma Adv. Res, Syngene Internatl., Hikal, Suven Life Sciences. Market Cap of Vivo Bio Tech is ₹40 Crs. While the median market cap of its peers are ₹2,746 Crs.
Is Vivo Bio Tech financially stable compared to its competitors?
Vivo Bio Tech seems to be less financially stable compared to its competitors. Altman Z score of Vivo Bio Tech is 1.29 and is ranked 8 out of its 8 competitors.
Does Vivo Bio Tech pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Vivo Bio Tech latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Vivo Bio Tech allocated its funds?
Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Capital Work in Progress
How strong is Vivo Bio Tech balance sheet?
Vivo Bio Tech balance sheet is weak and might have solvency issues
Is the profitablity of Vivo Bio Tech improving?
The profit is oscillating. The profit of Vivo Bio Tech is -₹2.86 Crs for TTM, ₹7.28 Crs for Mar 2025 and ₹2.53 Crs for Mar 2024.
Is the debt of Vivo Bio Tech increasing or decreasing?
Yes, The net debt of Vivo Bio Tech is increasing. Latest net debt of Vivo Bio Tech is ₹65.94 Crs as of Mar-26. This is greater than Mar-25 when it was ₹51.71 Crs.
Is Vivo Bio Tech stock expensive?
Vivo Bio Tech is not expensive. Latest PE of Vivo Bio Tech is 0, while 3 year average PE is 17.93. Also latest EV/EBITDA of Vivo Bio Tech is 5.04 while 3yr average is 6.04.
Has the share price of Vivo Bio Tech grown faster than its competition?
Vivo Bio Tech has given lower returns compared to its competitors. Vivo Bio Tech has grown at ~-14.99% over the last 8yrs while peers have grown at a median rate of 2.98%
Is the promoter bullish about Vivo Bio Tech?
Promoters seem not to be bullish about the company and have been selling shares in the open market. Latest quarter promoter holding in Vivo Bio Tech is 30.62% and last quarter promoter holding is 35.43%
Are mutual funds buying/selling Vivo Bio Tech?
There is Insufficient data to gauge this.